Healthcare News | BioTuesdays by Kilmer Lucas IR

Markets

Maxim ups Titan Pharma to buy with PT of $1

Maxim Group upgraded Titan Pharmaceuticals (NASDAQ:TTNP) to “buy” from “hold,” establishing a $1 price target as the company has raised capital and removed a financing overhang. The stock was quoted at 20 cents in...

October 23, 2019

Developments

Hepion to present CRV431’s potential in liver fibrosis at NASH summit

Hepion Pharmaceuticals’ (NASDAQ:HEPA) CSO, Dr. Daren Ure, will discuss the potential of the company’s lead candidate, CRV431, as a treatment for non-alcoholic steatohepatitis (NASH) at the third annual NASH summit. Dr...

October 23, 2019

Markets

Mackie ups Knight Therapeutics to buy; PT to $10.80 from $8.20

Mackie Research Capital upgraded Knight Therapeutics (TSX:GUD) to “buy” from “hold” and raised its price target to $10.80 from $8.20 after Knight’s planned acquisition of Grupo Biotoscana for $369-million (Canadian)...

October 23, 2019

Developments

Zenabis in cannabis cultivation accord with Tantalus Labs

Zenabis Global (TSX:ZENA) entered into an agreement with Tantalus Labs to grow and harvest cannabis plants from clones provided by Tantalus. The plants will be grown and harvested at the Zenabis Langley plant. Tantalus...

October 23, 2019

Developments

KemPharm presents patient-friendly dosing data for KP415 in ADHD

KemPharm (NASDAQ:KMPH) presented study results demonstrating the ability of KP415 to be administered without regard to food and via alternative dosing methods at the annual American Academy of Child and Adolescent...

October 23, 2019

Markets

Stifel starts Senseonics at buy; PT $2

Stifel initiated coverage of Senseonics Holdings (NYSE American:SENS) with a “buy” rating and $2 price target. The stock closed at 95 cents on Oct. 22. Senseonics is an emerging company with a long-duration, implantable...

October 23, 2019

Markets

SVB Leerink ups Aclaris Therapeutics to OP; PT to $3.50 from $1.50

SVB Leerink upgraded Aclaris Therapeutics (NASDAQ:ACRS) to “outperform” from “market perform” and raised its price target to $3.50 from $1.50, citing a new focus at the company. The stock closed at $1.41 on Oct. 21...

October 22, 2019

Developments

Titan Pharma to present two Probuphine posters at conference

Titan Pharmaceuticals (NASDAQ:TTNP) will present two posters on its buprenorphine implant, Probuphine, at the tenth American Conference of Pharmacometrics. Probuphine is a subdermal implant that provides six-month...

October 22, 2019

Developments

FDA accepts IntelGenx NDA resubmission for RIZAPORT

The FDA accepted IntelGenx’s (TSXV:IGX; OTCQX:IGXT) 505(b)(2) NDA resubmission for RIZAPORT VersaFilm for the treatment of acute migraines. The FDA also assigned a PDUFA goal date for completion of the NDA review of...

October 22, 2019

Developments

Zenabis cultivation output of dried cannabis up 21.8% in September

Zenabis Global’s (TSX:ZENA) cultivation output of dried cannabis reached 2,089 kg in September 2019, or 21.2% greater than its revised forecast output of 1,731 kg. Output at the company’s Zenabis Atholville plant...

October 21, 2019

Markets

HCW starts Dynavax Technologies at buy; PT $13

H.C. Wainwright initiated coverage of Dynavax Technologies (NASDAQ:DVAX) with a “buy” rating and $13 price target based on an outlook for the sales growth of the company’s marketed hepatitis B vaccine, Heplisav-B. The...

October 18, 2019

Developments

JPET publishes Hepion data highlighting CRV431’s potential to treat chronic liver diseases

Hepion Pharmaceuticals (NASDAQ:HEPA) CRV431 data from experimental models of fibrosis and non-alcoholic steatohepatitis (NASH) have been published in the peer-reviewed Journal of Pharmacology and Experimental...

October 16, 2019

Maxim ups Titan Pharma to buy with PT of $1

Hepion to present CRV431’s potential in liver fibrosis at NASH summit

Mackie ups Knight Therapeutics to buy; PT to $10.80 from $8.20

Zenabis in cannabis cultivation accord with Tantalus Labs

KemPharm presents patient-friendly dosing data for KP415 in ADHD

Stifel starts Senseonics at buy; PT $2

SVB Leerink ups Aclaris Therapeutics to OP; PT to $3.50 from $1.50

Titan Pharma to present two Probuphine posters at conference

FDA accepts IntelGenx NDA resubmission for RIZAPORT

Zenabis cultivation output of dried cannabis up 21.8% in September

HCW starts Dynavax Technologies at buy; PT $13

JPET publishes Hepion data highlighting CRV431’s potential to treat chronic liver diseases

General

More